Indaptus Therapeutics, Inc. – NASDAQ:INDP
Founder-led company
Indaptus Therapeutics stock price today
$7.38
+6.54
+782.88%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Indaptus Therapeutics stock price monthly change
-62.84%
month
Indaptus Therapeutics stock price quarterly change
-62.84%
quarter
Indaptus Therapeutics stock price yearly change
-52.37%
year
Indaptus Therapeutics key metrics
Market Cap | 11.05M |
Enterprise value | 5.32M |
P/E | -1.11 |
EV/Sales | N/A |
EV/EBITDA | -0.37 |
Price/Sales | N/A |
Price/Book | 0.60 |
PEG ratio | -0.13 |
EPS | -1.79 |
Revenue | N/A |
EBITDA | -15.86M |
Income | -14.97M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIndaptus Therapeutics stock price history
Indaptus Therapeutics stock forecast
Indaptus Therapeutics financial statements
| Jun 2023 | 0 | -3.24M | |
|---|---|---|---|
| Sep 2023 | 0 | -3.92M | |
| Dec 2023 | 1.92K | -4.00M | -207613.02% |
| Mar 2024 | 0 | -3.80M |
| Mar 2024 | 0 | -3.80M | |
|---|---|---|---|
| Sep 2025 | 0 | -2.94M | |
| Oct 2025 | 0 | -2.87M | |
| Dec 2025 | 0 | -2.78M |
Analysts Price target
Financials & Ratios estimates
| 2022-11-10 | -0.53 | -0.42 |
|---|---|---|
| 2023-03-17 | -0.37233 | -0.44 |
| Jun 2023 | 20844709 | 2.21M | 10.65% |
|---|---|---|---|
| Sep 2023 | 17794056 | 2.46M | 13.83% |
| Dec 2023 | 14923878 | 2.84M | 19.08% |
| Mar 2024 | 10948515 | 1.58M | 14.5% |
| Jun 2023 | -2.10M | 8M | 0 |
|---|---|---|---|
| Sep 2023 | -3.73M | 7M | 0 |
| Dec 2023 | -2.60M | -61.08K | 0 |
| Mar 2024 | -3.93M | 0 | 316.04K |
Indaptus Therapeutics alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Indaptus Therapeutics other data
4.91%
-9.18%
of INDP is owned by hedge funds
200.83K
-375.58K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 20150 | 0 |
| Nov 2022 | 10500 | 0 |
| Dec 2022 | 500 | 0 |
| Aug 2023 | 103352 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ANDERSON GLEN R. 10 percent owner | Common Stock | 23,934 | $2.34 | $56,006 | ||
Purchase | ANDERSON GLEN R. 10 percent owner | Common Stock | 35,064 | $2.12 | $74,336 | ||
Purchase | ANDERSON GLEN R. 10 percent owner | Common Stock | 44,354 | $1.94 | $86,047 | ||
Purchase | LITCHEV BOYAN VESSELINOV officer: Chief Medical Officer | Common Stock | 500 | $1.87 | $936 | ||
Purchase | LITCHEV BOYAN VESSELINOV officer: Chief Medical Officer | Common Stock | 500 | $1.83 | $915 | ||
Purchase | MECKLER JEFFREY A director, officer.. | Common stock | 9,600 | $1.9 | $18,240 | ||
Purchase | MECKLER JEFFREY A director, officer.. | Common stock | 400 | $1.76 | $706 | ||
Purchase | MECKLER JEFFREY A director, officer.. | Common stock | 10,308 | $2.8 | $28,862 | ||
Purchase | MECKLER JEFFREY A director, officer.. | Common stock | 8,632 | $2.57 | $22,184 | ||
Purchase | LINSCOTT WALT ADDISON officer: Chief Bu.. | Common stock | 150 | $2.62 | $393 |
-
What's the price of Indaptus Therapeutics stock today?
One share of Indaptus Therapeutics stock can currently be purchased for approximately $7.38.
-
When is Indaptus Therapeutics's next earnings date?
Unfortunately, Indaptus Therapeutics's (INDP) next earnings date is currently unknown.
-
Does Indaptus Therapeutics pay dividends?
No, Indaptus Therapeutics does not pay dividends.
-
How much money does Indaptus Therapeutics make?
Indaptus Therapeutics has a market capitalization of 11.05M. Indaptus Therapeutics made a loss 15.42M US dollars in net income (profit) last year or -$0.44 on an earnings per share basis.
-
What is Indaptus Therapeutics's stock symbol?
Indaptus Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "INDP".
-
What is Indaptus Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Indaptus Therapeutics?
Shares of Indaptus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Indaptus Therapeutics's key executives?
Indaptus Therapeutics's management team includes the following people:
- Mr. Jeffrey A. Meckler Chief Executive Officer & Director(age: 58, pay: $798,120)
- Mr. Walt Addison Linscott Esq. Chief Bus. Officer(age: 64, pay: $557,930)
- Mr. Nir Sassi Chief Financial Officer(age: 49, pay: $378,470)
- Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer & Director(age: 69, pay: $200,000)
-
Is Indaptus Therapeutics founder-led company?
Yes, Indaptus Therapeutics is a company led by its founder Dr. Michael J. Newman Ph.D..
-
How many employees does Indaptus Therapeutics have?
As Jul 2024, Indaptus Therapeutics employs 7 workers.
-
When Indaptus Therapeutics went public?
Indaptus Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 4 Aug 2015.
-
What is Indaptus Therapeutics's official website?
The official website for Indaptus Therapeutics is indaptusrx.com.
-
Where are Indaptus Therapeutics's headquarters?
Indaptus Therapeutics is headquartered at 3 Columbus Circle, New York, NY.
-
How can i contact Indaptus Therapeutics?
Indaptus Therapeutics's mailing address is 3 Columbus Circle, New York, NY and company can be reached via phone at +34 74809760.
Indaptus Therapeutics company profile:
Indaptus Therapeutics, Inc.
indaptusrx.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
3 Columbus Circle
New York, NY 10019
New York, NY 10019
CIK: 0001857044
ISIN: US45339J1051
CUSIP: 45339J105
